Publicaties Dissertaties 2013

Size: px
Start display at page:

Download "Publicaties 2013. Dissertaties 2013"

Transcription

1 Publicaties 2013 Dissertaties 2013 Vermeulen RP Quality management developments in cardiology ISBN: Promotiedatum: 13 februari 2013 Promotores: Copromotores: Prof.dr. M.P. van den Berg Dr. B.J.G.L. de Smet Dr. M.W.N. Nijsten Lok DJA Novel markers in chronic heart failure ISBN: Promotiedatum: 22 mei 2013 Promotores: Prof.dr. D.J. van Veldhuisen Dr. P. van der Meer Van Deursen VM Comorbidity in heart failure ISBN ISBN (PDF) ISBN (epub) Promotiedatum: 26 juni Promotores: Prof.dr. A.A. Voors Prof.dr. D.J. van Veldhuisen Copromotor: Dr. K. Damman De Vries, AE The use of computer decision support systems and telemonitoring in heart failure ISBN ISBN (electronic) Promotiedatum: 4 september 2013 Promotores: Prof.dr. H.L. Hillege Prof.dr. T. Jaarsma Prof.dr. R.J.J.M. Jorna Copromotor: Dr. M.H.L. van der Wal Fokkema ML Outcome after percutaneous coronary intervention ISBN: ISBN electronic version: Promotiedatum: 20 februari 1986 Promotores: Prof.dr. A.A. Voors Copromotor: Dr. B.J.G.L. de Smet Gu YL Intracoronary therapies & myocardial reperfusion in acute myocardial infarction ISBN: ISBN electronic version: Promotiedatum: 20 november 2013

2 Promotor: Copromotores: Prof.dr. F. Kuipers Dr. B.J.G.L. de Smet Dr. I.C.C. van der Horst Internationale tijdschriften Posafalvi A, Herkert JC, Sinke RJ, Van den Berg MP, Mogensen J, Jongbloed JD, Van Tintelen JP Clinical utility gene card for: dilated cardiomyopathy (CMD). Eur J Human Gen 2013;21: Engels GE, Gu YJ, Van Oeveren W, Rakhorst G, Mariani MA, Erasmus ME The utility of lung epithelium specific biomarkers in cardiac surgery: a comparison of biomarker profiles in on- and off-pump coronary bypass surgery. J Cardiothorac Surg 2013;8:4 Metra M, Cotter G, Davison BA,, Voors AA, et al Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX- AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013;2: Freling HG, Pieper PG, Vermeulen KM, Van Swieten JM, Sijens PE, Van Veldhuisen DJ, Willems TP Improved cardiac MRI volume measurements in patients with Tetralogy of Fallot by independent endsystolic and end-diastolic phase selection. PLoS One 2013;8 De Laat MWM, Pieper PG, Oudijk MA, Mulder BJM, Christoffels VM, Afink GB, Postma AV, Ris-Stalpers C The clinical and molecular relations between idiopathic preterm labor and maternal congenital heart disease. Reprod Sc 2013;2: De Vries AE, Van der Wal MHL, Nieuwenhuis MMW, De Jong RM, Van Dijk RB, Jaarsma T, Hillege HL Health professionals expectations versus experiences of internet-based telemonitoring: survey among heart failure clinics. J Med Intern Res 2013;1:73-83 Sinner MF, Wang N, Fox CS, Fontes JD, Rienstra M, Magnani JW, Vasan RS, Calderwood AH, Pencina M, Sullivan LM, Ellinor PT, Benjamin EJ Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am J Cardiol 2013;2: Groenweg JA, Van der Zwaag PA, Jongbloed JD, Cox MG, Vreeker A, De Boer RA, Van der Heijden JF, Van Veen TA, McKenna WJ, Van Tintelen JP, Dooijes D, Hauer RN Left-dominant arrhythmogenic cardiomyopathy in a large family: associated desmosomal or nondesmosomal genotype? Heart Rhythm 2013;10:548-59

3 Zuidersma M, Conradi HJ, Van Melle JP, Ormel J, De Jonge P Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. J Psychosom Res 2013;74:25-30 Manhenke C, Orn S, Von Haehling S, Wollert KC, Ueland T, Aukrust P, Voors AA, Squire I, Zannad F, Anker SD, Dickstein K Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. Int J Cardiol 2013;166: Van Veldhuisen DJ, McMurray JJ Pharmacological treatment of heart failure with preserved ejection fraction: a glimpse of light at the end of the tunnel? Eur J Heart Fail 2013;15:5-8 Udo EA, Van Hemel NM, Zuithoff NPA, Dijk WA, Hooijschuur CAM, Doevendans PA, Moons KGM Pacemaker follow-up: are the latest guidelines in line with modern pacemaker practice? Europace 2013;2: Westenbrink BD, Dorn GW Imaging the cardiac diet. Eur J Heart Fail 2013;2:123-4 Van der Bom T, Winter MM, Bouma BJ, Groenink M, Vliegen HW, Pieper PG, Van Dijk APJ, Sieswerda GT, Roos-Hesselink JW, Zwinderman AH, Mulder BJM Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial. Circulation 2013;3: Hyttel-Sorensen S, Austin T, Van Bel F, Benders M, Claris O, Dempsey EM, Fumagalli M, Gluud C, Hagmann C, Hellström-Westas L, Lemmers P, Naulaers G, Van Oeveren W, Pellicer A, Pichler G, Roll C, Støy LS, Wolf M, Greisen G Clinical use of cerebral oximetry in extremely preterm infants is feasible. Dan Med J 2013;60:A4533 Kneyber MC, Grotenhuis F, Berger RF, Ebels TW, Burgerhof JG, Albers MJ Transfusion of leukocyte-depleted RBC s is independently associated with increased morbidity after pediatric cardiac surgery. Pediatr Crit Care Med 2013;14: Gheorghiade M, Marti CN, Sabbah HN, Roessig L, Greene SJ, Böhm M, Burnett JC, Campia U, Cleland JG, Collins SP, Fonarow GC, Levy PD, Metra M, Pitt B, Ponikowski P, Sato N, Voors AA, Stasch JP, Butler J Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail Rev 2013;18: Swedberg K, Young JB, Anand IS,, Van Veldhuisen DJ Treatment of anemia with darbepoetin alfa in systolic heart failure. N Eng J Med 2013;13:1210-9

4 Lubitz SA, Rienstra M Genetic susceptibility to atrial fibrillation: does heart failure change our perspective? Eur J Heart Fail 2013;3:244-6 Heuvelman HJ, Arabkhani B, Cornette JMJ, Pieper PG, Bogers AJJC, Takkenberg JJM, Roos-Hesselink JW Pregnancy outcomes in women with aortic valve substitutes. Am J Cardiol 2013;3:382-7 Mahmud H, Ruifrok WP, Westenbrink BD, Cannon MV, Vreeswijk-Baudoin I, Van Gilst WH, Silljé HH, De Boer RA Suicidal erythrocyte death, eryptosis, as a novel mechanism in heart-failure associated anaemia. Cardiovasc Res 2013;98:37-46 Broekema FI, Van Oeveren W, Selten MH, Meijer RJ, De Wolf JT, Bos RR In vivo hemostatic efficacy of polyurethane foam compared to collagen and gelatin. Clin Oral Investig 2013;17: Erqou S, Lee CT,Suffoletto M, Echouffo-Tcheugui JB, De Boer RA, Van Melle JP, Adler AI Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: systematic review and meta-analysis Eur J Heart Fail 2013;15: Pieper PG Predicting the future in peripartum cardiomyopathy. Heart 2013;5:295-6 Lau CP, Gbadebo TD, Connolly SJ, Van Gelder IC, Capucci A, Gold MR, Israel CW, Morillo CA, Siu CW, Abe H, Carlson M, Tse HF, Hohnloser SH, Healey JS; ASSERT investigators Ethnic differences in atrial fibrillation using implanted cardiac devices. J Cardiovasc Electrophysiol 2013;24:381-7 Teerlink JR, Cotter G, Davison BA,, Voors AA, et al Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29-39 Van Veldhuisen DJ, Linssen GCM, Jaarsma T, Van Gilst WH, Hoes AW, Tijssen JGP, Paulus WJ, Voors AA, Hillege HL B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013;14: Kottgen A, Albrecht E, Teumer A,, Van der Harst P, et al Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet 2013;2: Groeneweg JA, Van der Zwaag PA, Jongbloed JD, Cox MG, Vreeker A, De Boer RA, Van der Heijden JF, Van Veen TA, McKenna WJ, Van Tintelen JP, Dooijes D, Hauer RN Left-dominant arrhythmogenic cardiomyopathy in a large family: associated desmosomal or nondesmosomal genotype? Heart Rhythm 2013;10:548-9

5 Fokkema ML, James SK, Albertsson P, Akerblom A, Cailas F, Eriksson P, Jensen J, Nilsson T, De Smet BJ, Sjogren I, Thorvinger B, Lagerqvist B Population trends in percutaneous coronary intervention; 20-year results from the SDCAAR (Swedish Coronary Angiography and Angioplasty Registry. J Amer Coll Cardiol 2013;12: Hummel YM, Wilde AA, Voors AA, Bugatti S, Hillege JL, Van den Berg MP Ventricular dysfunction in a family with long QT syndrome type 3. Europace 2013;15: Kortekaas KA, Hoogslag GE, De Boer RA, Dokter MM, Versteegh MI, Braun J, Marsan NA, Verwey HF, Delgado V, Schalij MJ, Klautz RJ Galectin-3 and left ventricular reverse remodelling after surgical mitral valve repair. Eur J Heart Fail 2013;15: Mulder BA, Schnabel RB, Rienstra M Predicting the future in patients with atrial fibrillation: who develops heart failure? Eur J Heart Fail 2013;4:366-7 Hoendermis ES, Van Melle JP Impaired right ventricular function and elevated pulmonary artery pressure: a lethal combination. Eur J Heart Fail 2013;25:363-5 McMurray JJ, Anand IS, Diaz R, Maggione AP, O Connor C, Pfeffer MA, Solomon SD, Tendera M, Van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB; on behalf of the RED-HF Committees Investigators Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF). Eur J Heart Fail 2013;15: Roberts JD, Herkert JC, Rutberg J, Nikkel SM, Wiesfeld ACP, Dooijes D, Gow RM, Van Tintelen JP, Gollob MH Detection of genomic deletions of PKP2 in arrhytmogenic right ventricular cardiomyopathy. Clin Genet 2013;5:452-6 Szymanski MK, Hillege HL, Danser AHJ, Garrelds IM, Schoemaker RG Elevated sensitivity to cardiac ischemia in proteinuric rats is independent of adverse cardiac remodeling. J Hypertens 2013;5: Hoekstra T, Jaarsma T, Van Veldhuisen DJ, Hillege HL, Sanderman R, Lesman-Leegte I Quality of life and survival in patients with heart failure. Eur J Heart Fail 2013;15: Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, Van Veldhuisen DJ, Van der Meer P, Jankowska EA Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 2013;4: Hoen PW, Rosmalen JGM, Schoevers RA, Huzen J, Van der Harst P, De Jonge P Association between anxiety but not depressive disorders and leukocyte telomere length after 2 years of follow-up in a population-bases sample. Psychol Med 2013;4:689-97

6 Kleijn L, Westenbrink BD, Van der Meer P Erythropoietin and heart failure: the end of a promise? Eur J Heart Fail 2013;5: Koene BM, Soliman Hamad MA, Bouma W, Mariani MA, Peels KC, Van Dantzig JM, Van Straten AH Impact of prosthesis-patient mismatch on early and late mortality after aortic valve replacement. J Cardiothorac Surg 2013;8:96 De Vries AE, Van der Wal MHL, Nieuwenhuis MMW, De Jong RM, Van Dijk RB, Jaarsma T, Hillege HL Perceived barriers of heart failure nurses and cardiologists in using clinical decision support systems in the treatment of heart failure patients. BMC Medical Inform Decis Mak 2013;13:54 Arsov S, Graaff R, Van Oeveren W, Steghmayr B, Sikole A, Rakhorst G, Smit AJ Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review. Clin Chem Lab Med 2013;4:1-10 Westenbrink BD, Edwards AG, Miyamoto S Conference report from the 2012 AHA scientific sessions in Los Angeles. Expert Opin Ther Targets 2013;6:733-7 Metra M, Cotter G, Davison BA,, Voors AA, et al Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX- AHF) development program: correlations with outcomes. J Am Coll Cardiol 2013;61: Dobre D, Rossignol P, Murin J, Parkhomenko A, Lamiral Z, Krum H, Van Veldhuisen DJ, Pitt B, Zannad F Statin therapy and clinical outcomes in myocardial infarction patients complicated by acute heart failure: insights from the EPHESUS trial. Eur J Heart Fail 2013;15:221-7 Johansson P, Lesman-Leegte I, Lundgren J, Hillege HL, Hoes A, Sanderman R, Van Veldhuisen DJ, Jaarsma T Time-course of depressive symptoms in patients with heart failure. J Psychosom Res 2013;3: Freling HG, Van Wijk K, Jaspers K, Pieper PG, Vermeulen KM, Van Swieten JM, Willems TP Impact of right ventricular endocardial trabeculae on volumes and function assessed by CMR in patients with tetralogy of Fallot. Int J Cardiovasc Imaging 2013;3: Groeneweg JA, Van der Zwaag, PA, Olde Nordkamp LR,, Wiesfeld AC,, Van den Berg MP, et al Arrhythmogenic right ventricle dysplasia/cardiomyopathy according to revised 2010 Task Force criteria with inclusion of non-desmosomal phospholamban mutation carriers. Am J Cardiol 2013;112: Ganesh SK, Tragante V, Guo W,, Van der Harst P, et al Loci influencing blood pressure identified using a cardiovascular gene-centric array. Hum Mol Genet 2013;8:

7 Hernández-Madrid, A, Svendsen JH, Lip GY, Van Gelder IC, Dobreanu D, Blomstrom-Lundqvist C Scientific Initiatives Committee, European Heart Rhythm Association (EHRA) Cardioversion for atrial fibrillation in current European practice: results of the European Heart Rhythm Association survey. Europace 2013;15:915-8 Testani JM, Damman K Venous congestion and renal function in heart failure it s complicated. Eur J Heart Fail 2013;6: Haase M, Muller C, Damman K, Murray PT, Kellum JA, Ronco C, McCullough PA Pathogenesis of cardiorenal syndrome type 1 in acute decompensated heart failure: Workgroup Statements from the Eleventh Conference of the Acute Dialysis Quality Initiative (ADQi). Contrib Nephrol 2013;182: Van der Meer P, Postmus D, Ponikowski P,, Voors AA The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. J Am Coll Cardiol 2013;19: Joosten MM, Gansevoort RT, Mukamal KJ, Van der Harst P, Geleijnse JM, Feskens EJM, Navis G, Bakker SJL Urinary and plasma magnesium and risk of ischemic heart disease. Am J Clin Nutr 2013;6: Schroten NF, Ruifrok WP, Kleijn L, Dokter MM, Silljé HH, Lambers Heerspink HJ, Bakker SJ, Kema IP, Van Gilst WH, Van Veldhuisen DJ, Hillege HL, De Boer RA Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial). Am Heart J 2013;166: Vida VL, Torregrossa G, De Franceschi, Padalino MA, Belli E, Berggren H, ÇiÇek S, Ebels T, Fragata J, Hoel TN, Horer J, Hraska V, Kostolny M, Lindberg H, Mueller C, Pretre R, Rosser B, Rubay J, Schreiber C, Speggiorin S, Tlaskal T, Stellin G; European Congenital Heart Surgeons Association (ECHSA) Pediatric coronary artery revascularization: a European multicenter study. Ann Thorac Surg 2013;96: Delewi R, IJff G, Van de Hoef TP, Hirsch A, Robbers LF, Nijveldt R, Van der Laan AM, Van der Vleuten PA, Lucas C. Tijssen JGP, Van Rossum AC, Zijlstra F, Piek JJ Pathological Q waves in myocardial infarction in patients treated by primary PCI. JACC Cardiovasc Imaging 2013; Den Dekker MAM, Van den Dungen JJAM, Tielliu IFJ, Tio RA, Jaspers MMJJR, Oudkerk M, Vliegenthart R Prevalence of severe subclinical coronary artery disease on cardiac CT and MRI in patients with extracardiac arterial disease. Eur J Vasc Endovasc Surg 2013;6:680-9 Meissner M, Wolters H, De Boer RA, Havinga R, Boverhof R, Bloks VW, Kuipers F, Groen AK Bile acid sequestration normalizes plasma cholesterol in hypercholesterolemic mice. No additional effect of physical activity. Atherosclerosis 2013;228:117-23

8 Rienstra M, Van Gelder IC A specialized atrial fibrillation clinic: improving care and costs for patients with atrial fibrillation. Europace 2013;15: Brignole A, Aurricchio A, Baron-Esquivias G,, Van Gelder IC, et al 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 2013;34: Minkman MMN, Vermeulen RP, Ahaus KTB, Huijsman R A survey study to validate a four phases development model for integrated care in the Netherlands. BMC Health Serv Res 2013;13:214 Fontes JD, Yamamoto JF, Larson MG, Wang N, Dallmeier D, Rienstra M, Schnabel RB, Vasan RS, Keaney JF, Benjamin EJ Clinical correlates of change in inflammatory biomarkers: the Framingham heart study. Atherosclerosis 2013;1: Gui J, Moore JH, Williams SM, Andrews P, Hillege HL, Van der Harst P, Navis G, Van Gilst WH, Asselbergs FW, Gilbert-Diamond D A simple and computationally efficient approach to multifactor dimensionality reduction analysis of genegene interactions for quantitative traits. PLoS One 2013;8 Kerdijk W, Rio RA, Mulder BF, Cohen-Schotanus J Cumulative assessment: strategic choices to influence students study effort. BMC Med Educ 2013:13:172 McCullough PA, Kellum JA, Haase M,, Damman K, et al Pathophysiology of the cardiorenal syndromes: executive summary from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQi). Contrib Nephrol 2013;182:82-98 Gheorghiade M, Fonarow GC, Van Veldhuisen DJ, Cleland JGF, Butler J, Epstein AE, Patel K, Aban IB, Aronow WS, Anker SD. Ahmed A Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J 2013;20:1489 Berndt SI, Gustafsson S, Magi R,, Van der Harst P, et al Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nature Genet 2013;5:501-U69 Franken R, Den Hartog AW, Van de Riet L, Timmermans J, Scholte AJ, Van den Berg MP, De Waard V, Zwinderman AH, Groenink M, Yip JW, Mulder BJM Clinical features differ substantially between Caucasian and Asian populations of Marfan syndrome. Circ J 2013;11:2793-8

9 Collier TJ, Pocock SJ, McMurray JJ, Zannad F, Krum H, Van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. Eur Heart J 2013;34: Van der Bom T, Winter MM, Groenink M, Vliegen HW, Pieper PG, Van Dijk APJ, Sieswerda GT, Roos- Hesselink JW, Zwinderman AH, Mulder BJM, Bouma BJ Right ventricular end-diastolic volume combined with peak systolic blood pressure during exercise identifies patients at risk for complications in adults with a systemic right ventricle. J Am Coll Cardiol 2013;10: Randall JC, Winkler TW, Kutalik Z,, Van der Harst P, et al Sex-stratified genome-wide association studies including individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet 2013;6 Westenbrink BD, Kleijn L, Van der Meer P Haemodilution is a mechanism of anaemia in patients with heart failure: reply. Eur J Heart Fail 2013;9: Schnabel RB, Rienstra M, Sullivan LM, et al Risk assessment for incident heart failure in individuals with atrial fibrillation. Eur J Heart Fail 2013;8:843-9 Salzberg SP, Van Bowen WJ, Driessen AH, Benussi S, Ylmaz A, Mariani M, Hyde J, Hunter S, Castella M Atrio-esophageal fistula following minimally invasive surgical atrial fibrillation ablation: separating fact from myth (letter to the editor). J Cardiovasc Electrophysiol 2013;24:E12-3 Van Rijsingen IA, Nannenberg EA, Arbustini E, Elliott PM, Mogensen J, Ast JF, Van der Kooi AJ, Van Tintelen JP, Van den Berg MP, Grasso M, Serio A, Jenkins S, Rowland C, Richard P, Wilde AA, Perrot A, Pankuweit S, Zwinderman AH, Charron P, Christiaans I, Pinto YM Gender-specific differences in major cardiac events and mortality in lamin A/C mutation carriers. Eur J Heart Fail 2013;15: Rienstra M, Lyass A, Murabito JM, Magnani JW, Lubitz SA, Massaro JM, Elinor PT, Benjamin EJ Reciprocal relations between physical disability, subjective health, and atrial fibrillation: The Framingham Heart Study. Am Heart J 2013;1:171-8 Assa S, Gansevoort RT, Westerhuis R, Kobold AC, Voors AA, De Jong PE, Bakker SJ, Franssen CF Determinants and prognostic significance of an intra-dialysis rise of cardiac troponin 1 measured by sensitive assay in hemodialyses patients. Clin Res Cardiol 2013;102: Maggioni AP, Dahlstrom U, Filippatos G,, Voors AA, et al EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESH-HF Pilot) Eur J Heart Fail 2013;7:808-17

10 Meyer S, Van der Meer P, Van Deursen VM, Jaarsma T, Van Veldhuisen DJ, Van der Wal MHL, Hillege HL, Voors AA Neurohormonal and clinic sex differences in heart failure. Eur Heart J 2013;32: Van der Linde D, Andrinopoulou ER, Oechslin EN,, Pieper PG, et al Congenital valvular aortic stenosis in Young adults: predictors for rate of progression of stenosis and aortic dilatation. Int J Cardiol 2013;2: Ebels T Atrial septal defect closure in the adult remains controversial, editorial comments. Eur J Cardiothorac Surg 2013;43:757-8 Lok DJ, Lok SI, Bruggink-André de la Porte PW, Badings E, Lipsic E, Van Wijngaarden J, De Boer RA, Van Veldhuisen DJ, Van der Meer P Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol 2013;102: Gheorghiade M, Patel K, Filippatos G, Anker SD, Van Veldhuisen DJ, Cleland JGF, Metra M, Aban IB, Greene SJ, Adams KF, McMurray JJV, Ahmed A Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail 2013;5:551-9 Wieringa WG, Lexis CPH, Dierckx GFH, Lipsic E, Tan ES, Schurer RAJ, Van der Werf HW, Van den Heuvel AFM, Suurmeijer AJH, Zijlstra F, De Smet BJGL, Pundziute G The feasibility of optical coherence tomography guided thrombus aspiration in patients with non-stelevation myocardial infarction after initial conservative therapy a pilot study. Int J Cardiol 2013;5: Schurer RA, Douglas YL, Van der Werf HW, Natour E, Van den Heuvel AF Use of the MitraClip in high-risk patients with severe heart failure: are we ready to identify the right candidate? Eur J Heart Fail 2013;15:715-6 Lok DJ, Klip IT, Lok SI, Bruggink-André de la Porte PW, Badings E, Van Wijgaarden J, Voors AA, De Boer RA, Van Veldhuisen DJ, Van der Meer P Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C- reactive protein, galectin-3, and high-sensitivity troponin-t) in patients with advanced chronic heart failure. Am J Cardiol 2013;112:831-7 Mulder BA, Van Veldhuisen DJ, Crijns HJGM, Tijssen JGP, Hillege HL, Alings M, Rienstra M, Groenveld HF, Van den Berg MP, Van Gelder IC, for the RACE II investigators Lenient vs. Strict rate controle in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II study. Eur J Heart Fail 2013;15:1311-8

11 Pundziute G Can coronary calcium scoring and computed tomography angiography serve as a gatekeeper for invasive coronary angiography in patients with new-onset heart failure? Eur J Heart Fail 2013;15:963-5 Juarez-Orozco LE, Glauche J, Alexanderson E, Zeebregts CJ, Boersma HH, Glaudemans AWJM, Dierckx RA, Van Veldhuisen DJ, Tio RA, Slart RHJA Myocardial perfusion reserve in spared myocardium: correlation with infarct size and left ventricular ejection fraction. Eur J Nucl Med Mol Imaging 2013;8: Zannad F, Garcia AA, Anker SD,, Voors AA, et al Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail 2013;10: Kaufmann SG, Westenbroek RE, Maass AH, Lange V, Renner A, Wischmeyer E, Bonz A, Muck J, Ertl G, Catterall WA, Scheuer T, Maier SKG Distribution and function of sodium channel subtypes in human atrial myocardium. J Mol Cell Cardiol 2013;61: Seferovic PM, Stoerk S, Filippatos G,, Van Veldhuisen DJ, et al Organization of heart failure management in European Society of Cardiology members countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. Eur J Heart Fail 2013;15: Voors AA, Dorhout B, Van der Meer P The potential role of valsartan+ahu377 (LCZ696) in the treatment of heart failure. Expert Opin Invest Drugs 2013;8: Wolff D, Van Melle JP, Berger RM, Ebels T The Fontan operation starts with the cavopulmonary shunt. J Am Coll Cardiol 2013;61: Eschalier R, McMurray JJ, Swedberg K, Van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B; EMPHASIS-HF investigators Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (eplerenone in mild patients hospitalization and survival study in heart failure). J Am Coll Cardiol 2013;62: Kerstjens-Frederikse WS, Bongers EMHF, Roofthooft MTR, Leter EM, Douwes JM, Van Dijk A, Vonk- Noordegraaf A, Dijk-Bos KK, Hoefsloot LH, Hoendermis ES, Gille JJP, Sikkema-Raddats B, Hofstra RMW, Berger RMF TBX4 mutations (small patella syndrome) are associated with childhood-onset pulmonary arterial hypertension. J Med Genet 2013;8:500-6 Van Gelder IC, Van Veldhuisen DJ, Lip GY New oral anticoagulants in heart failure. Eur J Heart Fail 2013;15:966-73

12 Neyt M, Van den Bruel A, Smit Y, De Jonge N, Erasmus M, Van Dijk D, Vlayen J Cost-effectiveness of continuous-flow left ventricular assist devices. Int J Technol Assess Health Care 2013;29: Paul DS, Albers CA, Rendon A, Voss K, Stephens J, HaemGen Consortium, Van der Harst P, Chambers JC, Soranzo N, Ouwehand WH, Deloukas P Maps of open chromatin highlight cell type-restricted patterns of regulatory sequence variation at hematological trait loci. Genome Res 2013;23: Den Hoed M, Eijgelsheim M, Esko T,, Van der Harst P, Van Gilst WH, et al Identification of heart rate associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet 2013;6:621 Sikkema-Raddats B, Johansson LF, De Boer EN, Almomani R, Boven LG, Van den Berg MP, Van Spaendonck-Zwarts KY, Van Tintelen JP, Sijmons RH, Jongbloed JDH, Sinke RJ Targeted next-generation sequencing can replace sanger sequencing in clinical diagnostics. Hum Mutat 2013;34: Lam MK, Al-Ansari S, Van Dam GM, Tio RA, Breek JC, Slart RH, Hillebrands JL, Zeebregts CJ Single chain VEGF/Cy5.5 targeting VEGF receptors to indicate atherosclerotic plaque instability. Mol Imaging Biol 2013;15: Fokkema ML, Kleijn L, Van der Meer P, Belonje AM, Achterhof SK, Hillege HL, van t Hof A, Jukema JW, Peels HO, Henriques JP, Ten Berg JM, Vos J, Van Gilst WH, Van Veldhuisen DJ, Voors AA Long term effects of epoetin alfa in patients with ST-elevation myocardial infarction. Cardiovasc Drugs Ther 2013;27:433-9 De Boer RA, Edelmann F, Cohen-Solal A, Mamas MA, Maisel A, Pieske B Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail 2013;15: Riezebos-Brilman A, Verschuuren EAM, Van Son WJ, Van Imhoff GW, Brügemann J, Blokzijl H, Niesters HGM The clinical course of hepatitis E virus infection in patients of a tertiary Dutch hospital over a 5 yearperiod. J Clin Virol 2013;3: Brouwers FP, Van Gilst WH, Van Veldhuisen DJ The changing face of heart failure: are we really making progress? Eur J Heart Fail 2013;15:960-2 Bourge RC, Fleg JL, Fonarow GC,, Van Veldhuisen DJ, et al Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med 2013;8:701-8 Voors AA, Van der Meer P Heart failure in the young. J Am Coll Cardiol 2013;20: Groenink M, Den Hartog AW, Franken R, Radonic T, De Waard V, Timmermans J, Scholte AJ, Van den Berg MP, Spijkerboer AM, Marquering HA, Zwinderman AH, Mulder BJM

13 Losartan reduced aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J 2013;34: Arrigoni SC, Willems TP, Mungroop HE, Van den Heuvel F, Ebels T Lusoria flap for the management of aortic coarctation in an eight-year-old child. World J Pediatr Congenit Heart Surg 2013;4:302-4 De Jong AM, Van Gelder IC, Vreeswijk-Baudoin I, Cannon MV, Van Gilst WH, Maass AH Atrial remodeling is directly related to end-diastolic left ventricular pressure in a Mouse model of ventricular pressure overload. PLoS One 2013;8:e72651 Mehmood SI, Borleffs JCC, Tio RA Medical students in search of research? Med Teach 2013;10:873-4 Maass AH, Van Veldhuisen DJ Contemporary use of devices in heart failure. Clin Pharmacol Ther 2013;94:433-5 De Boer RA, Van der Velde AR Galectin-3: a new biomarker for heart failure progression and prognosis. J Lab Med 2013;5: Koyak Z, De Groot JR, Bouma BJ, Van Gelder IC, Budts W, Zwinderman AH, Mulder BJ Symptomatic but not asymptomatic non-sustained ventricular tachycardia is associated with appropriate implantable cardioverter therapy in tetralogy of Fallot. Int J Cardiol 2013;167: Schuuring MJ, Vis JC, Van Dijk AP, Van Melle JP, Vliegen HW, Pieper PG, Sieswerda GT, De Bruin-Bon RH, Mulder BJ, Bouma BJ Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail 2013;14:690-8 Hyttel-Sorensen S, Austin T, Van Bel F, Benders M, Claris O, Dempsey E, Fumagalli M, Greisen G, Grevstad B, Hagmann C, Hellström-Westas L, Lemmers P, Lindschou J, Naulaers G, Van Oeveren W, Pellicer A, Pichler G, Roll C, Skoog M, Winkel P, Wolf M, Gluud C A phase II randomized clinical trial on cerebral near-infrared spectroscopy plus a treatment guideline versus treatment as usual for extremely preterm infants during the first three days of life (SafeBoosC): study protocol for a randomized controlled trial. Trials 2013;14:120 Munneke AJ, Rakhorst G, Petersen AH, Van Oeveren W, Prop J, Erasmus ME Flush at room temperature followed by storage on ice creates the best lung graft preservation in rats. Transpl Int 2013;26: Rienstra M, Van Gelder IC Ventricular rate control of atrial fibrillation in heart failure. Heart Fail Clin 2013;9:

14 Van Veldhuisen DJ, Van Gelder IC, Ahmed A, Gheorghiade M Digoxin for patients with atrial fibrillation and heart failure: paradise lost or not? Eur Heart J 2013;34: Vis JC, Duffels MG, Mulder P, De Bruin-Bon RH, Bouma BJ, Berger RM, Hoendermis ES, Van Dijk AP, Mulder BJ Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. Int. J. Cardiol 2013;164:64-9 Koyak Z, Kroon B, De Groot JR, Wagenaar LJ, Van Dijk AP, Mulder BA, Van Gelder IC, Post MC, Mulder BJ, Bouma BJ Efficacy of antiarrhythmic drugs in adults with congenital heart disease and supraventricular tachycardias. Am J Cardiol 2013;112: Gheorghiade M, Marti CN, Sabbah HN, Roessig L, Greene SJ, Böhm M, Burnett JC, Campia U, Cleland JG, Collins SP, Fonarow GC, Levy PD, Metra M, Pitt B, Ponikowski P, Sato N, Voors AA, Stasch JP, Butler J Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail Rev 2013;18: Gottlieb SS, Stebbins A, Voors AA, Hasselblad V, Ezekowitz JA, Califf RM, O Connor CM, Starling RC, Hernandez AF Effects of nesiritide and predictors of urine output in acute decompensated heart failure; results from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure). J Am Coll Cardiol 2013;13: Brouwers FP, De Boer RA, Van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, Hillege HL, Van Veldhuisen DJ, Van Gilst WH Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 2013;34: McMurray JJ, Anand IS, Diaz R, Maggioni AP, O Connor C, Pfeffer MA, Solomon SD, Tendera M, Van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB; on behalf of the RED-HF Committees Investigators Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). Eur J Heart Fail; 2013;15: Nauta FL, Scheven L, Meijer E, Van Oeveren W, De Jong PE, Bakker SJ, Gansevoort RT Glomerular and tibular damage markers in individuals with progressive albuminuri. Clin J Soc Nephrol 2013;8: Fiuzat M, O Connor CM, Gueyffier F,, Voors AA, et al Biomarker-guided therapies in heart failure: a forum for unified strategies. J Card Fail 2013;8:592-9 Yu L, Ruifrok WP, Meissner M, Bos EM, Van Goor H, Sanjabi B, Van der Harst P, Pitt B, Goldstein IJ, Koerts JA, Van Veldhuisen DJ, Bank RA, Van Gilst WH, Silljé HH, De Boer RA Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013;6:107-17

15 Damman K Neutrophil gelatinase-associated lipocalin and worsening renal function in acute heart failure: the plot thickens. J Cardiovasc Med 2013;9:636-6 Kraai IH, Vermeulen KM, Luttik MLA, Hoekstra T, Jaarsma T, Hillege HL Preferences of heart failure patients in daily clinical practice: quality of life or longevity? Eur J Heart Fail 2013;10: Liu H, Luiten PGM, Eisel ULM, De Jongste MJL, Schoemaker RG Depression after myocardial infarction: TNF-alpha-induced alterations of the blood-brain barrier and its putative therapeutic implications. Neurosc Biobeh Rev 2013;4: Arsov S, Trajceska L, Van Oeveren W, Smit AJ, Dzekova P, Stegmayr B, Sikole A, Rakhorst G, Graaff R Increase in skin autofluorescence and release of heart-type fatty acid binding protein in plasma predicts mortality of hemodialysis patients. Artif Organs 2013;37:E Holmes MV, Simon T, Exeter HJ,, Van der Harst P, et al Secretory phospholipase A(2)-IIA and cardiovascular disease. J Am Coll Cardiol 2013;21: Verweij N, Mahmud H, Mateo Leach I, De Boer RA, Brouwers FP, Yu H, Asselbergs FW, Struck J, Bakker SJ, Gansevoort RT, Munroe PB, Hillege HL, Van Veldhuisen DJ, Van Gilst WH, Silljé HH, Van der Harst P Genome-wide association study on plasma levels of midregional-proadrenomedullin and C-terminal-proendothelin-1. Hypertension 2013;61:602-8 Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, De Boer RA, Poirier F, Lacolley P, Zannad F, Rossignol P, López-Andrés N Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013;33:67-75 Groenweg JA, Van der Zwaag PA, Nordkamp LRAO,, Wiesfeld ACP, et al Arrhythmogenic right ventricular dysplasia/cardiomyopathy according to revised 2010 Task Force criteria with inclusion of non-desmosomal phospholamban mutation carriers. Am J Cardiol 2013;8: Backus BE, Six AJ, Kelder JC,, Tio R, et al A prospective validation of the HEART score for chest pain patients at the emergency department. Int J Cardiol 2013;3: Dullaart RPF, Van Pelt LJ, Kwakernaat AJ, Dikkeschei BD, Van der Horst ICC, Tio RA Plasma lipoprotein-associated phospholipase A(2) mass is elevated in STEMI compared to non-stemi patients but does not discriminate between myocardial infarction and non-cardiac chest pain. Clin Chim Acta 2013;424: Voors AA Trial data resolve gaps in evidence-based treatment. Nat Rev Cardiol 2013;10:67-8

16 Pahari DR, Gu YL, Van Oeveren W, El-Essawi A, Harringer W, Brouwer RM Effect of minimized perfusion circuit on brain injury markers carnosinase and brain-type fatty binding protein in coronary artery bypass grafting patients. Artif Organs 2013;37: Van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian AS, Muntendam P, Van Veldhuisen DJ, De Boer RA Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 2013;6: Brouwer CA, Postma A, HLH Hooimeijer, Smit AJ, Vonk JM, Van Roon AM, Van den Berg MP, Dolsma WV, Lefrandt JD, Bink-Boelkens MTE, Zwart N, De Vries EGE, Tissing WJE, Gietema JA Endothelial damage in long-term survivors of childhood cancer. J Clin Oncol 2013;31: Kirchhof P, Breithardt G, Aliot E,, Van Gelder IC, et al Personalized management of atrial fibrillation: proceedings from the fourth Atrial Fibrillation competence NETwork/European heart Rhythm Association consensus conference. Europace 2013;11: Damman P, Kampinga MA, Van der Horst ICC, Woudstra P, Grundeken MJ, Kuijt WJ, Harskamp RE, Nijsten MWN, Zijlstra F, Tijssen JGP, De Smet BJ, De Winter RJ Multiple biomarkers for the prediction of short and long-term mortality after ST-segment elevation myocardial infarction: the Amsterdam Groningen collaboration. J Thromb Thrombolys 2013;1:42-6 Gheorghiade M, Vaduganathan M, Fonarow GC, Greene SJ, Greenberg BH, Liu PP, Massie BM, Mehra MR, Metra M, Zannad F, Cleland JGF, Van Veldhuisen DJ, Shah AN, Butler J Anticoagulation in heart failure: current status and future direction. Heart Fail Rev 2013;6: Mahmud H, Ruifrok WP, Westenbrink BD, Cannon MV, Vreeswijk-Baudoin I, Van Gilst WH, Silljé HH, De Boer RA Suicidal erythrocyte death, eryptosis, as a novel mechanism in heart failure-associated anemia. Cardiovasc Res 2013;98:37-46 Van Spaendonck-Zwarts KY, Van Rijsingen IAW, Van den Berg MP, Lekanne Deprez RH, Post JG, Van Mil AM, Asselbergs FW, Christiaans I, Van Langen IM, Wilde AAM, De Boer RA, Jongbloed JDH, Pinto YM, Van Tintelen JP Genetic analysis in 418 index patients with idiopathic dilated cardiomyopathy: overview of 10 years experience. Eur J Heart Fail 2013;15: Pellicer A, Greisen G, Benders M, Claris O, Dempsey E, Fumagalli M, Gluud C, Hagmann C, Hellström- Westas L, Hyttel-Sorensen S, Lemmers P, Naulaers G, Pichler G, Roll C, Van Bel F, Van Oeveren W, Skoog M, Wolf M, Austin T The SafeBoosC phase II randomized clinical trial: a treatment guideline for targeted near-infrared-derived cerebral tissue oxygenation versus standard treatment in extremely preterm infants. Neonatology 2013;104:171-8

17 Camm AJ, Lip GY, Caterina RD,., Van Gelder IC, et al Actualización de las guias de la Sociedad Europea de Cardiologia (ESC) para el manejo de la fibrilación auricular de 2010 Elaborado en colaboración con la Asociación Europea del Ritmo Cardiaco. Rev Esp Cardiol 2013;66:54.e1-44.e24 Groenveld HF, Tijssen JG, Crijns HJ, Van den Berg MP, Hillege HL, Alings M, Van Veldhuisen DJ, Van Gelder IC; RACE II Investigators Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation). J Am Cardiol 2013;61:741-8 Wolff D, Ebels T, Van Melle JP N-terminal pro brain natriuretic hormone in Fontan patients: heart failure or circulatory failure? Eur J Heart Fail 2013;15:602-3 Franken R, Den Hartog AW, De Waard V, Engele L, Radonic T, Lutter R, Timmermans J, Scholte AJ, Van den Berg MP, Zwinderman AH, Groenink M, Mulder BJM Circulating transforming growth factor-β as a prognostic biomarker in Marfan syndrome. Int J Cardiol 2013;168: Bouma W, Wijdh-den Hamer IJ, Klinkenberg TJ, Kuijpers M, Bijleveld A, Van der Horst IC, Erasmus ME, Gorman JH 3rd, Gorman RC, Mariani MA Mitral valve repair for post-myocardial infarction papillary muscle rupture. Eur J Cardiothorac Surg 2013;44: Pozzoli A, Klinkenberg TJ, De Maat GE, Mariani MA Cardiac dynamic magnetic resonance of a giant lung carcinoma invading the left atrium: do not let the imaging fool you. Eur J Cardiothoracic Surg 2013;44:377-8 Buijs RVC, Willems TP, Tio RA, Boersma HH, Tielliu IFJ, Slart RHJA, Zeebregts CJ Calcification as a risk factor for rupture of abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2013;5:542-8 Widder J, Klinkenberg TJ, Ubbels JF, Wiegman EM, Groen HJ, Langendijk JA Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy? Radiother Oncol 2013;107: Munneke AJ, Rakhorst G, Petersen AH, Van Oeveren W, Prop J, Erasmus ME Flush at room temperature followed by storage on ice creates the best lung graft preservation in rats. Transpl Int 2013;26: Van De Wauwer C, Munneke AJ, Engels GE, Berga FM, Rakhorst G, Nijsten MW, Mariani MA, Erasmus ME In situ lung perfusion is a valuable tool to assess lungs from donation after circulatory death donors category I-II. Transpl Int 2013;26:485-92

18 Snijder PM, De Boer RA, Bos EM, Van den Born JC, Ruifrok WP, Vreeswijk-Baudoin, Van Dijk MC, Hillebrands JL, Leuvenink HG, Van Goor H Gaseous hydrogen sulfide protects against myocardial ischemia-reperfusion injury in mice partially independent from hypometabolism. PLoS One 2013;8:e63291 De Jong AM Maass AH, Oberdorf-Maass SU, De Boer RA, Van Gilst WH, Van Gelder IC Cyclical stretch induces structural changes in atrial myocytes. J Cell Mol Med 2013;17: Codd V, Nelson CP, Albrecht E,, De Boer RA,, Van Veldhuisen DJ,, Van der Harst P, et al Identification of seven loci affecting mean telomere lenght and their association with disease. Nat Genet 2013;45:422-7 Den Hoed M, Eijgelsheim M, Esko T,, De Boer RA, et al Identification of heart rate-associated loci and their effect on cardiac conduction and rhythm disorders. Nat Genet 2013;45: Zuidersma M, Conradi HJ, Van Melle JP, Ormel J, De Jonge P Self-reported depressive symptoms, diagnosed clinical depression and cardiac morbidity and mortality after myocardial infarction. Int J Cardiol 2013;167: Buijs RV, Willems TP, Tio RA, Boersma HH, Tielliu IF, Slart RH, Zeebregts CJ Current state of experimental imaging modalities for risk assessment of abdominal aortic aneurysm. J Vasc Surg 2013;57:851-9 Den Hartog AW, Franken R, De Witte P, Radonic T, Marquering HA, Van der Steen WE, Timmermans J, Scholte AJ, Van den Berg MP, Zwinderman AH, Mulder BJM, Groenink M Aortic disease in patients with Marfan syndrome: aortic volume assessment for surveillance. Radiology 2013;268:370-7 Kirchhof P, Breithardt G, Aliot E.,, Van Gelder IC, et al. Personalized management of atrial fibrillation: Proceedings from the fourth atrial fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace 2013;15: Van Rijsingen IA, Bakker A, Azim D, Hermans-van Ast JF, Van der Kooi AJ, Van Tintelen JP, Van den Berg MP, Christiaans I, Lekanne Dit Deprez RH, Wilde AA, Zwinderman AH, Meijers JC, Grootemaat EA, Nieuwland R, Pinto YM, Pinto-Sietsma JS Lamin A/C mutation is independently associated with an increased risk of arterial and venous thromboembolic complications. Int J Cardiol 2013;168:472-7 Gheorghiade M, Vaduganathan M, Greene SJ, Mentz RJ, Adams KF Jr, Anker SD, Arnold M, Baschiera F, Cleland JG, Cotter G, Fonarow GC, Giordano C, Metra M, Misselwitz F, Mühlhofer E, Nodari S, Frank Franken R, Den Hartog AW, Van de Riet L, Timmermans J, Scholte AJ, Van den Berg MP, De Waard V, Zwinderman AH, Groenink M, Yip JW, Mulder BJM Clinical features differ substantially between Caucasian and Asian populations of Marfan syndrome Circulation Journal 2013;77:2793-8

19 Pieper PG, Balci A, Aarnoudse JG, Kampman MA, Sollie KM, Groen H, Mulder BJ, Oudijk MA, Roos- Hesselink JW, Cornette J, Van Dijk AP, Spaanderman ME, Drenthen W, Van Veldhuisen DJ; ZAHARA II investigators Uteroplacental blood flow, cardiac function, and pregnancy outcome in women with congenital heart disease. Circulation 2013;128: De Maat GE, Pozzoli A, Scholten MF, Hillege HL, Van Gelder IC, Alfieri OR, Benussi S, Mariani MA Surgical minimally invasive pulmonary vein isolation for lone atrial fibrillation: midterm results of a multicenter study. Innovations (Phila) 2013;8:410-5 Yin M, Westenbrink B, Meissner M, Van Gilst WH, De Boer RA Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: a translational perspective for the cardiologist. Int J Cardiol 2013;169: Yu H, Tigchelaar W, Lu B, Van Gilst WH, e Boer RA, Westenbrink BD, Silljé HH AKIP1, a cardiac hypertrophy induced protein that stimulates cardiomyocyte growth via the Akt pathway. Int J Mol Sci 2013;14: Kuijpers M, Klinkenberg TJ, Bouma W, De Jongste MJ, Mariani MA Single-port one-stage bilateral thorascopic sympathicotomy for severe hyperhidrosis: prospective analysis of a standardized approach. J Cardiothorac Surg 2013;6:216 Pozzoli A, De Maat GE, Hillege HL, Boogaard JJ, Natour E, Mariani MA Severe thrombocytopenia and its clinical impact after implant of the stentless Freedom Solo bioprosthesis. Ann Thorac Surg 2013;96: Altena R, Van Veldhuisen DJ Heart matters: cardiovascular complications related to cancer treatment. Fut Oncol 2013;2: Sandker SC, Mecozzi G, Van Buiten A, Mariani MA, Buikema H, Grandjean JG Adventitial dissection: a simple and effective way to reduce radial artery spasm in coronary bypass surgery. Interact Cardiovasc Thorac Surg 2013;17:784-9 Van Oeveren W Obstacles in haemocompatibility testing. Scientifica (Cairo) 2013;2013: Akkerman OW, Van Altena R, Klinkenberg T, Brouwers AH, Bongaerts AHH, Van der Werf TS, Alffenaar JW Drug concentration in lung tissue in multidrug-resistant tuberculosis. Eur Resp J 2013;6: Buikema JW, Van der Meer P, Sluijter JPG, Domian IJ Concise review: engineering myocardial tissue: the convergence of stem cells biology and tissue engineering technology.

20 Stem Cells 2013;12: Meyer S, Van der Meer P, Massie BM,, Voors AA, et al Sex-specific acute heart failure phenotypes and outcomes from PROTECT. Eur J Heart Fail 2013;12: Robbers LFHJ, Delewi R, Nijveldt R,, Van der Vleuten PA, Tio RA, et al Myocardial infarct heterogeneity assessment by late gadolinium enhancement cardiovascular magnetic resonance imaging shows predictive value for ventricular arrhythmia development after acute myocardial infarction. Eur Heart J Cardiovasc Imaging 2013;12: Kwakernaak AJ, Waanders F, Slagman MC, Dokter MM, Laverman GD, De Boer RA, Navis G Sodium restriction on top of renin-angiotensin-aldosterone system blockade increases circulating levels of N-acetyl-seryl-aspartyl-lysyl-proline in chronic kidney disease patients. J Hypert 2013;31: Yu H, Tigchelaar W, Koonen DP, Patel HH, De Boer RA, Van Gilst WH, Westenbrink BD, Silljé HH AKIP1 expression modulates mitochondrial function in rat neonatal cardiomyocytes. PLoS One 2013;8:e80815

Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years

Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years Claim#:021914-174 Initials: J.T. Last4SSN: 6996 DOB: 5/3/1970 Crime Date: 4/30/2013 Status: Claim is currently under review. Decision expected within 7 days Claim#:041715-334 Initials: M.S. Last4SSN: 2957

More information

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains

More information

How to control atrial fibrillation in 2013 The ideal patient for a rate control strategy

How to control atrial fibrillation in 2013 The ideal patient for a rate control strategy How to control atrial fibrillation in 2013 The ideal patient for a rate control strategy L. Pison, MD Advances in Cardiac Arrhythmias and Great Innovations in Cardiology - Torino, September 28 th 2013

More information

Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology

Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology Atrial Fibrillation 2014 How to Treat How to Anticoagulate Allan Anderson, MD, FACC, FAHA Division of Cardiology Projection for Prevalence of Atrial Fibrillation: 5.6 Million by 2050 Projected number of

More information

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent

More information

1p36 and the Heart. John Lynn Jefferies, MD, MPH, FACC, FAHA

1p36 and the Heart. John Lynn Jefferies, MD, MPH, FACC, FAHA 1p36 and the Heart John Lynn Jefferies, MD, MPH, FACC, FAHA Director, Advanced Heart Failure and Cardiomyopathy Services Associate Professor, Pediatric Cardiology and Adult Cardiovascular Diseases Associate

More information

INHERIT. The Lancet Diabetes & Endocrinology In press

INHERIT. The Lancet Diabetes & Endocrinology In press INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy a Randomized Intervention Trial with losartan Anna Axelsson, Kasper Iversen, Niels Vejlstrup, Carolyn

More information

Diagnostic and Therapeutic Procedures

Diagnostic and Therapeutic Procedures Diagnostic and Therapeutic Procedures Diagnostic and therapeutic cardiovascular s are central to the evaluation and management of patients with cardiovascular disease. Consistent with the other sections,

More information

Atrial Fibrillation An update on diagnosis and management

Atrial Fibrillation An update on diagnosis and management Dr Arvind Vasudeva Consultant Cardiologist Atrial Fibrillation An update on diagnosis and management Atrial fibrillation (AF) remains the commonest disturbance of cardiac rhythm seen in clinical practice.

More information

Atrial Fibrillation Cardiac rate control or rhythm control could be the key to AF therapy

Atrial Fibrillation Cardiac rate control or rhythm control could be the key to AF therapy Cardiac rate control or rhythm control could be the key to AF therapy Recent studies have proven that an option of pharmacologic and non-pharmacologic therapy is available to patients who suffer from AF.

More information

How should we treat atrial fibrillation in heart failure

How should we treat atrial fibrillation in heart failure Advances in Cardiac Arrhhythmias and Great Innovations in Cardiology Torino, 23/24 Ottobre 2015 How should we treat atrial fibrillation in heart failure Matteo Anselmino Dipartimento Scienze Mediche Città

More information

ECG may be indicated for patients with cardiovascular risk factors

ECG may be indicated for patients with cardiovascular risk factors eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,

More information

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with

More information

on behalf of the AUGMENT-HF Investigators

on behalf of the AUGMENT-HF Investigators One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Heart Failure* Douglas

More information

How do you decide on rate versus rhythm control?

How do you decide on rate versus rhythm control? Heart Rhythm Congress 2014 How do you decide on rate versus rhythm control? Dr Ed Duncan Consultant Cardiologist & Electrophysiologist Define Rhythm Control DC Cardioversion Pharmacological AFFIRM study

More information

ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)

ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL) ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL) By Prof. Dr. Helmy A. Bakr Mansoura Universirty 2014 AF Classification: Mechanisms of AF : Selected Risk Factors and Biomarkers for AF: WHY AF? 1. Atrial fibrillation

More information

Publicaties 2011. Dissertaties 2011

Publicaties 2011. Dissertaties 2011 Publicaties 2011 Dissertaties 2011 Ruifrok WPT Erythropoietin in heart failure. Effects beyond erythropoiesis ISBN: 978-90-816328-1-2 ISBN: 978-90-816328-2-9 elektronische versie Promotiedatum: 12 januari

More information

Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease

Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Heart Failure Center Hadassah University Hospital Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Israel Gotsman MD The Heart Failure Center, Heart Institute Hadassah University

More information

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1

More information

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG

More information

Treatment of cardiogenic shock

Treatment of cardiogenic shock ACUTE HEART FAILURE AND COMORBIDITY IN THE ELDERLY Treatment of cardiogenic shock Christian J. Wiedermann, M.D., F.A.C.P. Associate Professor of Internal Medicine, Medical University of Innsbruck, Austria

More information

A randomized, controlled trial comparing the efficacy of carvedilol vs. metoprolol in the treatment of atrial fibrillation

A randomized, controlled trial comparing the efficacy of carvedilol vs. metoprolol in the treatment of atrial fibrillation A randomized, controlled trial comparing the efficacy of carvedilol vs. metoprolol in the treatment of atrial fibrillation Gabriel Sayer Lay Abstract: Atrial fibrillation is a common form of irregular,

More information

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. INTRODUCTION Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. Although decrease in cardiovascular mortality still major cause of morbidity & burden of disease.

More information

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department Sohil Pothiawala FAMS (EM), MRCSEd (A&E), M.Med (EM), MBBS Consultant Dept. of Emergency Medicine Singapore General Hospital

More information

Rudolf de Boer. Paula Da Costa Martins. Ralph van Oort. Kevin Vernooij. Daniël Pijnappels. Lynda Juffermans. Toon van Veen. Peter van der Meer

Rudolf de Boer. Paula Da Costa Martins. Ralph van Oort. Kevin Vernooij. Daniël Pijnappels. Lynda Juffermans. Toon van Veen. Peter van der Meer Paula Da Costa Martins Ralph van Oort Lynda Juffermans Kevin Vernooij Daniël Pijnappels Toon van Veen Rudolf de Boer Linda van Laake Kim Van der Heiden Matthijs Boekholdt Peter van der Meer Blanche Schroen

More information

Surgeons Role in Atrial Fibrillation

Surgeons Role in Atrial Fibrillation Atrial Fibrillation Surgeons Role in Atrial Fibrillation Steven J Feldhaus, MD, FACS 2015 Cardiac Symposium September 18, 2015 Stages of Atrial Fibrillation Paroxysmal (Intermittent) Persistent (Continuous)

More information

ATRIAL FIBRILLATION: Scope of the Problem. October 2015

ATRIAL FIBRILLATION: Scope of the Problem. October 2015 ATRIAL FIBRILLATION: Scope of the Problem October 2015 Purpose of the Presentation Review the worldwide incidence and prognosis associated with atrial fibrillation (AF) Identify the types of AF, clinical

More information

CURRICULUM VITAE. 2003 2006 Bachelor of Science, Psychology Faculty of Social and Behavioral Sciences, Tilburg University, Tilburg, Netherlands

CURRICULUM VITAE. 2003 2006 Bachelor of Science, Psychology Faculty of Social and Behavioral Sciences, Tilburg University, Tilburg, Netherlands CURRICULUM VITAE PERSONAL INFORMATION Date of birth: January 11, 1985 Nationality: Dutch Work address: Tilburg University Warandelaan 2 5037 AB Tilburg d.schoormans@uvt.nl EDUCATION 2003 2006 Bachelor

More information

Automatic External Defibrillators

Automatic External Defibrillators Last Review Date: May 27, 2016 Number: MG.MM.DM.10dC2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth

More information

Management of Pacing Wires After Cardiac Surgery

Management of Pacing Wires After Cardiac Surgery Management of Pacing Wires After Cardiac Surgery David E. Lizotte, Jr. PA C, MPAS, FAPACVS President, Association of Physician Assistants in Cardiovascular Surgery Conflicts: None Indications 2008 Journal

More information

Stroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2

Stroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2 Bleeding/Clotting Risk Evaluation Tools for Atrial Fibrillation Patients Before prescribing anticoagulants, providers should weigh the risk of thrombosis against the risk of bleeding. The tools below can

More information

ATRIAL FIBRILLATION RATE VS RHYTHM CONTROL NCVH BIRMINGHAM 2014

ATRIAL FIBRILLATION RATE VS RHYTHM CONTROL NCVH BIRMINGHAM 2014 ATRIAL FIBRILLATION RATE VS RHYTHM CONTROL NCVH BIRMINGHAM 2014 Facts 4 million or so people have atrial fibrillation 16 billion dollars spent yearly in USA 30% of strokes attributable to AF and AFL 3-5

More information

Implantable Cardioverter Defibrillator Treatment: Benefits and Pitfalls in the Currently Indicated Population. Carel Jan Willem Borleffs

Implantable Cardioverter Defibrillator Treatment: Benefits and Pitfalls in the Currently Indicated Population. Carel Jan Willem Borleffs Implantable Cardioverter Defibrillator Treatment: Benefits and Pitfalls in the Currently Indicated Population Carel Jan Willem Borleffs The studies described in this thesis were performed at the Department

More information

Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013. Reference: NHSCB/A09/PS/b

Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013. Reference: NHSCB/A09/PS/b Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013 Reference: NHS Commissioning Board Clinical Commissioning Policy Statement: Percutaneous

More information

Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona

Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona Areas to be covered Historical, current, and future treatments for various cardiovascular disease: Atherosclerosis (Coronary

More information

Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Brief Comparison of Four Agents

Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Brief Comparison of Four Agents Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Brief Comparison of Four Agents Abbreviations AF: Atrial fibrillation ARISTOTLE: Apixaban for Reduction in Stroke and Other Thromboembolic

More information

Recurrent AF: Choosing the Right Medication.

Recurrent AF: Choosing the Right Medication. In the name of God Shiraz E-Medical Journal Vol. 11, No. 3, July 2010 http://semj.sums.ac.ir/vol11/jul2010/89015.htm Recurrent AF: Choosing the Right Medication. Basamad Z. * Assistant Professor, Department

More information

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38 Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac

More information

Atrial Fibrillation and Cardiac Device Therapy RAKESH LATCHAMSETTY, MD DIVISION OF ELECTROPHYSIOLOGY UNIVERSITY OF MICHIGAN HOSPITAL ANN ARBOR, MI

Atrial Fibrillation and Cardiac Device Therapy RAKESH LATCHAMSETTY, MD DIVISION OF ELECTROPHYSIOLOGY UNIVERSITY OF MICHIGAN HOSPITAL ANN ARBOR, MI Atrial Fibrillation and Cardiac Device Therapy RAKESH LATCHAMSETTY, MD DIVISION OF ELECTROPHYSIOLOGY UNIVERSITY OF MICHIGAN HOSPITAL ANN ARBOR, MI Outline Atrial Fibrillation What is it? What are the associated

More information

Atrial Fibrillation and Heart Failure: A Cause or a Consequence

Atrial Fibrillation and Heart Failure: A Cause or a Consequence Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November

More information

Main Effect of Screening for Coronary Artery Disease Using CT

Main Effect of Screening for Coronary Artery Disease Using CT Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,

More information

Listen to your heart: Good Cardiovascular Health for Life

Listen to your heart: Good Cardiovascular Health for Life Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular

More information

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate

More information

Atrial Fibrillation Based on ESC Guidelines. Moshe Swissa MD Kaplan Medical Center

Atrial Fibrillation Based on ESC Guidelines. Moshe Swissa MD Kaplan Medical Center Atrial Fibrillation Based on ESC Guidelines Moshe Swissa MD Kaplan Medical Center Epidemiology AF affects 1 2% of the population, and this figure is likely to increase in the next 50 years. AF may long

More information

INTRODUCTION TO EECP THERAPY

INTRODUCTION TO EECP THERAPY INTRODUCTION TO EECP THERAPY is an FDA cleared, Medicare approved, non-invasive medical therapy for the treatment of stable and unstable angina, congestive heart failure, acute myocardial infarction, and

More information

Cardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease

Cardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease Cardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease What is Cardiac Rehabilitation? Cardiac rehabilitation is a comprehensive exercise, education, and behavior modification

More information

Results of streamlined regional ambulance transport and subsequent treatment of acute abdominal aortic aneurysm

Results of streamlined regional ambulance transport and subsequent treatment of acute abdominal aortic aneurysm CHAPTER 6 Results of streamlined regional ambulance transport and subsequent treatment of acute abdominal aortic aneurysm JW Haveman, A Karliczek, ELG Verhoeven, IFJ Tielliu, R de Vos, JH Zwaveling, JJAM

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND: STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention

More information

CTA OF THE EXTRACORONARY HEART

CTA OF THE EXTRACORONARY HEART CTA OF THE EXTRACORONARY HEART Charles White MD Director of Thoracic Imaging Department of Radiology University of Maryland NO DISCLOSURES CWHITE@UMM.EDU CARDIAC CASE DISTRIBUTION Coronary CTA 30% ED chest

More information

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

More information

Hello. I would like to think everyone for coming this morning. I m going to talk about heart disease in pregnancy.

Hello. I would like to think everyone for coming this morning. I m going to talk about heart disease in pregnancy. Hello. I would like to think everyone for coming this morning. I m going to talk about heart disease in pregnancy. 1 I have a few objectives for this talk. First, we ll review the normal, anticipated chambers

More information

A focus on atrial fibrillation

A focus on atrial fibrillation A focus on atrial fibrillation Is being female really a risk factor for stroke? Dr Justin Mariani MBBS BMedSci PhD FRACP FCSANZ Consultant Cardiologist and Interventional Heart Failure Specialist Alfred

More information

Non-Invasive Risk Predictors in (Children with) Pulmonary Hypertension

Non-Invasive Risk Predictors in (Children with) Pulmonary Hypertension Ideal risk prognosticator Easy to acquire Non-Invasive Risk Predictors in (Children with) Pulmonary Hypertension Safe -- Non-invasive Robust Gerhard-Paul Diller Astrid Lammers Division of Adult Congenital

More information

Anticoagulants in Atrial Fibrillation

Anticoagulants in Atrial Fibrillation Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives

More information

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic

More information

Version 1 2015. Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen

Version 1 2015. Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen Version 1 2015 Module guide International Master Program Cardiovascular Science University of Göttingen Part 1 Theoretical modules Synopsis The Master program Cardiovascular Science contains four theoretical

More information

Potential Causes of Sudden Cardiac Arrest in Children

Potential Causes of Sudden Cardiac Arrest in Children Potential Causes of Sudden Cardiac Arrest in Children Project S.A.V.E. When sudden death occurs in children, adolescents and younger adults, heart abnormalities are likely causes. These conditions are

More information

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological

More information

Rikshospitalet, University of Oslo

Rikshospitalet, University of Oslo Rikshospitalet, University of Oslo Controversies in the optimal management of ischemic heart failure From myocardial infarction to heart failure How do we prevent this? European Society of Cardiology 23.05.2011

More information

Management of Symptomatic Atrial Fibrillation

Management of Symptomatic Atrial Fibrillation Management of Symptomatic Atrial Fibrillation John F. MacGregor, MD, FHRS Associate Medical Director, Cardiac Electrophysiology PeaceHealth St. Joseph Medical Center, Bellingham, WA September 18, 2015

More information

Heart Disorders Glossary

Heart Disorders Glossary Heart Disorders Glossary ABG (Arterial Blood Gas) Test: A test that measures how much oxygen and carbon dioxide are in the blood. Anemia: A condition in which there are low levels of red blood cells in

More information

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa 1999. Objectives. No disclosures, no conflicts

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa 1999. Objectives. No disclosures, no conflicts Cardiac Rehabilitation: From the other side of the glass door No disclosures, no conflicts Charles X. Kim, MD, FACC, ABVM Objectives 1. Illustrate common CV benefits of CV rehab in real world practice.

More information

PRACTICAL APPROACH TO SVT. Graham C. Wong MD MPH Division of Cardiology Vancouver General Hospital University of British Columbia

PRACTICAL APPROACH TO SVT. Graham C. Wong MD MPH Division of Cardiology Vancouver General Hospital University of British Columbia PRACTICAL APPROACH TO SVT Graham C. Wong MD MPH Division of Cardiology Vancouver General Hospital University of British Columbia CONDUCTION SYSTEM OF THE HEART SA node His bundle Left bundle AV node Right

More information

Managing the Patient with Atrial Fibrillation

Managing the Patient with Atrial Fibrillation Pocket Guide Managing the Patient with Atrial Fibrillation Updated April 2012 Editor Stephen R. Shorofsky, MD, Ph.D. Assistant Editors Anastasios Saliaris, MD Shawn Robinson, MD www.hrsonline.org DEFINITION

More information

Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements

Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements Salmaan Kanji, Pharm.D. The Ottawa Hospital The Ottawa Hospital Research Institute Conflict of Interest No financial, proprietary

More information

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics

More information

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor

More information

Antiplatelet and Antithrombotics From clinical trials to guidelines

Antiplatelet and Antithrombotics From clinical trials to guidelines Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories

More information

1. Geluk CA Coronary risk stratification. From PREVEND to the prevention of coronary events. ISBN: 978-90-367-3258-1 Promotiedatum: 16 januari 2008

1. Geluk CA Coronary risk stratification. From PREVEND to the prevention of coronary events. ISBN: 978-90-367-3258-1 Promotiedatum: 16 januari 2008 PUBLICATIES 2008 Dissertaties 1. Geluk CA Coronary risk stratification. From PREVEND to the prevention of coronary events. ISBN: 978-90-367-3258-1 Promotiedatum: 16 januari 2008 Promotores: Prof.dr. F.

More information

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize

More information

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of

More information

Protocol. Cardiac Rehabilitation in the Outpatient Setting

Protocol. Cardiac Rehabilitation in the Outpatient Setting Protocol Cardiac Rehabilitation in the Outpatient Setting (80308) Medical Benefit Effective Date: 07/01/14 Next Review Date: 09/15 Preauthorization No Review Dates: 07/07, 07/08, 05/09, 05/10, 05/11, 05/12,

More information

NEW ADVANCES IN MYOCARDIAL INFARCTION THERAPY: THE REGENERATION APPROACH

NEW ADVANCES IN MYOCARDIAL INFARCTION THERAPY: THE REGENERATION APPROACH NEW ADVANCES IN MYOCARDIAL INFARCTION THERAPY: THE REGENERATION APPROACH Giovanni Esposito, MD, PhD Dipartimento di Cardiologia, Cardiochirurgia ed Emergenze Cardiovascolari Laboratorio di Emodinamica

More information

1. Bruggink-André de la Porte PWF ISBN : 978-90-902-3824-1 Effects of heart failure management programmes Promotiedatum: 16 januari 2009

1. Bruggink-André de la Porte PWF ISBN : 978-90-902-3824-1 Effects of heart failure management programmes Promotiedatum: 16 januari 2009 Publicaties 2009 Dissertaties 2009 1. Bruggink-André de la Porte PWF ISBN : 978-90-902-3824-1 Effects of heart failure management programmes Promotiedatum: 16 januari 2009 Promotores: Prof.dr. A.W. Hoes

More information

Innovation Platform: Sudden Cardiac Death

Innovation Platform: Sudden Cardiac Death Innovation Platform: Sudden Cardiac Death Prof. dr. Bart Loeys CRC Antwerp General Assembly VzW Board of Directors Strategic Advisory Board Staff: 1 executive director 1 ICT manager 1 financial administration

More information

1 Congestive Heart Failure & its Pharmacological Management

1 Congestive Heart Failure & its Pharmacological Management Harvard-MIT Division of Health Sciences and Technology HST.151: Principles of Pharmocology Instructor: Prof. Keith Baker 1 Congestive Heart Failure & its Pharmacological Management Keith Baker, M.D., Ph.D.

More information

WETENSCHAPPELIJKE OUTPUT THORAXCENTRUM UMCG, 2008

WETENSCHAPPELIJKE OUTPUT THORAXCENTRUM UMCG, 2008 WETENSCHAPPELIJKE OUTPUT THORAXCENTRUM UMCG, 2008 Dissertaties 1. Geluk CA Coronary risk stratification. From PREVEND to the prevention of coronary events. ISBN: 978-90-367-3258-1 Promotiedatum: 16 januari

More information

Atherosclerosis of the aorta. Artur Evangelista

Atherosclerosis of the aorta. Artur Evangelista Atherosclerosis of the aorta Artur Evangelista Atherosclerosis of the aorta Diagnosis Classification Prevalence Risk factors Marker of generalized atherosclerosis Risk of embolism Therapy Diagnosis Atherosclerosis

More information

Perioperative Cardiac Evaluation

Perioperative Cardiac Evaluation Perioperative Cardiac Evaluation Caroline McKillop Advisor: Dr. Tam Psenka 10-3-2007 Importance of Cardiac Guidelines -Used multiple times every day -Patient Safety -Part of Surgical Care Improvement Project

More information

How do you decide on rate versus rhythm control?

How do you decide on rate versus rhythm control? How do you decide on rate versus rhythm control? Dr. Mark O Neill Consultant Cardiologist & Electrophysiologist Assumptions Camm et al. EHJ 2010;Sept 25 epub Choice of strategy: Criteria for consideration

More information

Adult Cardiac Surgery ICD9 to ICD10 Crosswalks

Adult Cardiac Surgery ICD9 to ICD10 Crosswalks 164.1 Malignant neoplasm of heart C38.0 Malignant neoplasm of heart 164.1 Malignant neoplasm of heart C45.2 Mesothelioma of pericardium 198.89 Secondary malignant neoplasm of other specified sites C79.89

More information

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center

More information

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,

More information

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology Objectives Acute Coronary Syndromes Epidemiology and Health Care Impact Pathophysiology Unstable Angina NSTEMI STEMI Clinical Clues Pre-hospital Spokane County EMS Epidemiology About 600,000 people die

More information

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION

More information

25-hydroxyvitamin D: from bone and mineral to general health marker

25-hydroxyvitamin D: from bone and mineral to general health marker DIABETES 25 OH Vitamin D TOTAL Assay 25-hydroxyvitamin D: from bone and mineral to general health marker FOR OUTSIDE THE US AND CANADA ONLY Vitamin D Receptors Brain Heart Breast Colon Pancreas Prostate

More information

Presenter Disclosure Information

Presenter Disclosure Information 2:15 3 pm Managing Arrhythmias in Primary Care Presenter Disclosure Information The following relationships exist related to this presentation: Raul Mitrani, MD, FACC, FHRS: Speakers Bureau for Medtronic.

More information

Steven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators

Steven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From the CoreValve US Pivotal Trial Steven J. Yakubov,

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Computed Tomography to Detect Coronary Artery Calcification File Name: computed_tomography_to_detect_coronary_artery_calcification Origination: 3/1994 Last CAP Review 11/2014 Next

More information

The author has no disclosures

The author has no disclosures Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author

More information

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY Care Pathway Triage category ATRIAL FIBRILLATION PATHWAY ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY AF/ FLUTTER IS PRIMARY REASON FOR PRESENTATION YES NO ONSET SYMPTOMS OF AF./../ TIME DURATION OF AF

More information

MEDICAL POLICY SUBJECT: CARDIAC REHABILITATION. POLICY NUMBER: 8.01.14 CATEGORY: Therapy/ Rehabilitation

MEDICAL POLICY SUBJECT: CARDIAC REHABILITATION. POLICY NUMBER: 8.01.14 CATEGORY: Therapy/ Rehabilitation MEDICAL POLICY SUBJECT: CARDIAC REHABILITATION PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy

More information

Care of the Post-Cardiac Surgery Patient. Lundy J. Campbell, M.D. Associate Professor University of California

Care of the Post-Cardiac Surgery Patient. Lundy J. Campbell, M.D. Associate Professor University of California Care of the Post-Cardiac Surgery Patient Lundy J. Campbell, M.D. Associate Professor University of California Post-Operative Issues Post-op atrial fibrillation Acute kidney injury Acute respiratory failure

More information

Resuscitation in congenital heart disease. Peter C. Laussen MBBS FCICM Department Critical Care Medicine Hospital for Sick Children Toronto

Resuscitation in congenital heart disease. Peter C. Laussen MBBS FCICM Department Critical Care Medicine Hospital for Sick Children Toronto Resuscitation in congenital heart disease Peter C. Laussen MBBS FCICM Department Critical Care Medicine Hospital for Sick Children Toronto Evolution of Congenital Heart Disease Extraordinary success: Overall

More information

Atrial Fibrillation Peter Santucci, MD Revised May, 2008

Atrial Fibrillation Peter Santucci, MD Revised May, 2008 Atrial Fibrillation Peter Santucci, MD Revised May, 2008 Atrial fibrillation (AF) is an irregular, disorganized rhythm characterized by a lack of organized mechanical atrial activity. The atrial rate is

More information

Mitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation. Michael Acker, MD For the CTSN Investigators AHA November 2013

Mitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation. Michael Acker, MD For the CTSN Investigators AHA November 2013 Mitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation Michael Acker, MD For the CTSN Investigators AHA November 2013 Acknowledgements Supported by U01 HL088942 Cardiothoracic

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION

STROKE PREVENTION IN ATRIAL FIBRILLATION STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients

More information

CONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA

CONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA CONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA Stephen A. Boorjian, MD Professor of Urology Vice Chair of Research Director, Urologic Oncology Fellowship Department of Urology Mayo Clinic, Rochester,

More information

HYPERCHOLESTEROLAEMIA STATIN AND BEYOND

HYPERCHOLESTEROLAEMIA STATIN AND BEYOND HYPERCHOLESTEROLAEMIA STATIN AND BEYOND Andrea Luk Division of Endocrinology Department of Medicine & Therapeutics The Chinese University of Hong Kong HA Convention 4 May 2016 Statins reduce CVD and all-cause

More information